Navigation Links
Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
Date:5/29/2008

Dr. Mielke Continues his Collaboration With Kiadis Pharma on ATIR(TM)

AMSTERDAM, May 29 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today the clinical development collaboration for its lead product ATIR(TM) with Dr. Stephan Mielke and Professor Dr. Hermann Einsele from the Allogeneic Stem Cell Transplant Center, Division of Hematology and Oncology, Department of Internal Medicine II at the Julius-Maximilians University of Wurzburg, Germany. Principal investigator of this collaboration will be Dr. Mielke.

Previously, Dr. Mielke initiated the ongoing phase II clinical study for ATIR(TM) as principal investigator at the Hematology Branch of the National Heart, Lung and Blood Institute (NHLBI) at the National Institutes of Health (NIH) in Bethesda, Maryland, USA, together with Dr. John Barrett, Chief of the Allogeneic Stem Cell Transplant Section at the Hematology Branch. The investigators selected ATIR(TM) for a clinical study after a pre-clinical research program and have published the pre-clinical data showing promising results with Kiadis Pharma's ATIR(TM) in eliminating alloreactive T-cells from donor grafts (Mielke et al. Blood 2008). Dr. Mielke and colleagues additionally developed a reliable large scale manufacturing protocol with a "GMP-like" semi-closed system for cell processing with ATIR(TM).

"We are extremely pleased with this collaboration which shows the interest of leading transplantation physicians to continue working with our lead product ATIR(TM) as well as to participate in setting up our next clinical study in Europe," says Dr. Manja Bouman, CEO of Kiadis Pharma.

According to Dr. Mielke selective allodepletion with ATIR(TM) carries significant potential for improving the outcome of mismatched (haploidentical ) transplants by allowing early immune reconstitution with less severe or no acute Graft versus Host Disease (GvHD). Therefore, Dr. Mielke and his team and Kiadis Pharma are planning to initiate a clinical phase III study for mismatched (haploidentical) transplantations in blood cancer patients at the Julius-Maximilians University of Wurzburg.

About ATIR(TM)

ATIR(TM) is designed to prevent life-threatening acute GvHD by eliminating the immune cells from the donor graft that otherwise attack the patient's body. Useful donor immune cells that can fight infections and remaining tumor cells are, however, spared, allowing rapid and safe donor immune reconstitution post transplantation. Acute GvHD is a major complication of allogeneic bone marrow transplantations. By preventing the occurrence of acute GvHD, ATIR(TM) enables the use of a mismatched donor and consequently addresses a significant limitation in bone marrow transplantations, which is the timely availability of a donor. Moreover, it could improve the general outcome of bone marrow transplants.

About Kiadis Pharma

Kiadis Pharma is an oncology company focused specifically on complications and limitations of bone marrow transplantations in blood cancer patients. The company has three products in clinical development that offer novel treatment options for terminally ill blood cancer patients and address high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands with facilities in Groningen, The Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit http://www.kiadis.com.


'/>"/>
SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017 Visiomed, ... and services since 1997, is changing the landscape ... technology providing patients with pro-active, custom-made solutions. Recognizing ... for instant and affordable healthcare without walls, Visiomed ... high-level devices developed with healthcare professionals that is ...
(Date:2/23/2017)... -- ITL Limited, ( ASX: ITD ), an innovative diversified healthcare ... ended 31 December 2016 compared with the previous corresponding period. A ... here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: 1.2 ... $15.7m; up 11%) Profit before tax of $2.12m ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and Strategies ... Fibromyalgia market. The research answers the following questions: ... and their clinical attributes? How are they positioned in the Global ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... With ProGlass Prism users now have the ability to ... control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass position ... With ProGlass Prism users are given the tools and effects to generate a ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business ... in radiology marketing programs at the annual Building Better Radiology Marketing Programs ... Worth Hotel in Fort Worth, Texas. Nine awards are given out in five categories. ...
(Date:2/23/2017)... ... February 23, 2017 , ... On February ... a letter to withdraw previous guidance issued by the Obama Administration ... guidance issued in May 2016 by the Obama Administration came in response to ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon ... TV’s “Mama June: From Not to Hot,” which will begin airing on February 24, ... known to millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Dr. David Mahon ... Henderson, NV 89052. Dr. Mahon was named a 2017 Top Patient Rated Henderson ... is an online directory that recognizes local physicians and dentists who have earned high ...
Breaking Medicine News(10 mins):